Squaric Acid Labeling Precursors for Stable Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing radiological imaging and theranostic procedures for cancers, particularly those targeting prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAP), and farnesyl pyrophosphate synthase (FPPS), face challenges in achieving high tumor selectivity and stability, with current labeling precursors often requiring elaborate trial-and-error methods to optimize affinity and stability.
Innovation Solution
Development of labeling precursors comprising chelators or fluorination groups coupled with targeting vectors via linkers and spacers, utilizing squaric acid residues to enhance the efficiency and specificity of radiotracers for PSMA, FAP, and FPPS, allowing for improved tumor cell targeting and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional labeling precursors are used with traditional coupling methods, then the synthesis process is simpler, but the tumor selectivity and stability are insufficient
Solution Approach 1:
The patent introduces squaric acid as an intermediary coupling component between the chelator and targeting vector. This mediator provides multiple coupling positions and enables the formation of stable conjugates with improved tumor selectivity, resolving the contradiction between simplicity and performance by adding a functional intermediate layer that enhances reliability without excessive complexity
Solution Approach 2:
The patent creates composite labeling precursor structures by combining chelators, squaric acid residues, and targeting vectors into integrated conjugates. This composite approach allows the system to achieve superior tumor selectivity and stability through the synergistic combination of multiple functional components, each contributing specific properties to the overall molecule
2Reliability
If elaborate trial-and-error methods are used to optimize labeling precursors, then the affinity and stability are improved, but the development time and complexity increase
Solution Approach 1:
The patent performs preliminary structural design by incorporating squaric acid residues with specific coupling characteristics into the labeling precursor framework before biological testing. This pre-optimization of the chemical structure based on known squaric acid coupling properties reduces the need for extensive trial-and-error experimentation, thereby improving affinity and stability while reducing development time
Solution Approach 2:
The patent systematically varies parameters such as the number of squaric acid residues (one or two), linker lengths, and targeting vector configurations to optimize the balance between affinity, stability, and development efficiency. By changing these structural parameters in a controlled manner, the patent achieves improved reliability without requiring exhaustive trial-and-error screening of all possible combinations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new labeling precursors demonstrate enhanced tumor selectivity and stability, facilitating effective diagnostic imaging and therapeutic interventions for prostate and stromal carcinomas, with improved uptake and retention in tumor cells.
Implementation Method 1
the labeling precursors comprise a chelator for the effective and stable complexation of the radioisotope
Implementation Method 2
the labeling precursors comprise a chelator for the effective and stable complexation of the radioisotope as an essential chemical component and a biological targeting vector as a functional component which binds to target structures in the tumor tissue
Data Source
AI summary
The invention relates to a marking precursor comprising a chelator or fluorination group for radiolabelling with 44SC, 47SC, 55Co, 62Cu, 64Cu, 67Cu, 66Ga, 67Ga, 68Ga, 89Zr, 86Y, 90Y, 90Nb, 99mTc, 111In, 135Sm, 140Pr, 159Gd, 149Tb, 160Tb, 161Tb, 165Er, 166Dy, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 213Bi and 225Ac or with 18F, 131I or 211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.